Introduction: Proton pump inhibitors (PPIs) largely used drug to treat gastroesophageal disease such as gastric ulcers. Moreover, in recent years, several studies suggest that PPIs have important anti-cancer effect in monotherapy and or combination with chemotherapy.
Objective: The aim of this study was to investigate whether esomeprazole and pantoprazole exhibit anti-cancer effect alone or could enhance chemosensitivity of CML cell line K562 to imatinib.
Method: Human chronic myeloid leukemia (CML) cells were cultured and treated with different concentrations of esomeprazole, pantoprazole, and imatinib alone. Also these cells exposed to imatinib + esomeprazole and imatinib + pantoprazole combinations, respectively and incubated 24 h. The antiproliferative activities of the (PPIs) alone or in combination of imatinib was evaluated using the XTT colorimetric assay.
Results: According to experimental data, neither PPIs showed any cytotoxicity on the K562 cell line at all concentrations except at 500 and 1000 µM. However, when combined with imatinib separately, they were found to have significant anti-cancer effects on K562 cells when compared to cell lines treated with imatinib alone (p<0.05).Conclusions: Taken together, the inhibition of V-ATPase via esomeprazole and pantoprazole might enhance the chemosensitivity of imatinib in CML cells. However, further studies are needed to be able to utilize PPIs in CML.
Chronic myeloid leukemia, esomeprazole, pantoprazole, V-ATPase
|Subjects||Health Care Sciences and Services|
|Published Date||Aralık 2018|
|Journal Section||Basic Science Research Articles|
|Publication Date||December 29, 2018|
|Published in Issue||Year 2018, Volume 40Issue 4|